This post is part of an ongoing series summarizing state-based psychedelic reforms intended for policy professionals.
Arizona
House Bill 2871 by state Rep. Justin Wilmeth (R-Phoenix), which would have allocated funding to ibogaine research, was folded into the state’s general appropriations bill and signed by the governor on June 27th. Reason Foundation has published an analysis on why Arizona’s joining Texas to fund ibogaine clinical trials marks an important step in the momentum to gain federal approval for the drug.
Senate Bill 1555 by state Sen. T.J. Shope (R-16) will legalize a pharmaceutical version of synthetic psilocybin at the state level if approved by the Food and Drug Administration (FDA). The bill passed on June 26th. The bill, as originally written, would have authorized a market for state-regulated psilocybin-assisted therapy, but was heavily amended.
Colorado
Colorado regulators are reportedly considering therapeutic use of iboga within the state’s regulated psychedelics program. Colorado would be the first state to offer legal iboga services. Under Proposition 122, a ballot initiative that created a regulated market for psilocybin therapy, the state can consider other botanical psychedelics. The Colorado Natural Medicines Advisory Board must first determine how to manage potential safety concerns and how licensees would be able to produce the compound.
Louisiana
Senate Resolution 186 from state Sen. Patrick McMath (R-11) would create a task force to study the use of psychedelics for veterans.
Massachusetts
H1858 (previously House Docket 188) from state Rep. Marc Lombardo (R-22nd Middlesex) would reduce the penalties for possession of psilocybin. It would impose a $100 fine for possession of less than one gram.
H1726 (previously House Docket 3895), from state Rep. Homar Gómez (D-2nd Hampshire), would direct courts to dismiss any arrest for possession of psilocybin by adults over 21 as long as their actions had no visible defects to the health or safety of another person.
H1624 (previously House Docket 4243) from state Rep. Mike Connolly (D-26th Middlesex) would create a psychedelics task force to study equity in psychedelic access.
All three bills received a joint session hearing on July 15th, 2025, but show no indication yet of next steps.
Michigan
House Bill 4686 from state Rep. Mike McFall (D-14) would effectively legalize the possession of psilocybin for Michiganders diagnosed with post-traumatic stress disorder. The bill does not create an affirmative legalization of psilocybin but exempts possession for treatment of PTSD from state law relating to the prohibition of illicit substances.
Mississippi
Mississippi lawmakers will hold an informational hearing about ibogaine on August 28. Reason Foundation research director Geoffrey Lawrence is expected to testify. Bryan Hubbard, CEO of Americans for Ibogaine, is also set to testify.
Oregon
House Bill 3817 (multiple sponsors) would have authorized the Oregon Health Authority to study the use of ibogaine for a range of mental health issues, such as anxiety. It failed to pass before the legislature adjourned.